Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 274

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 274
---
 development of REM-001for the treatment of CMBC. The grant will be received in twotranches: approximately $ 1,250for the period July 1, 2023, to June 30, 2024, and approximately $ 750for the period July 1, 2024, to June 30, 2025. As a result of receiving the grant, the REM-001, 15-patientclinical trial was restarted. The grant is expended to the Company as a reimbursement of expenditures incurred. During the three months ended September 30, 2024, the Company received $ 236 (2023 - $ 13)for grants received against research and development expenditures in the period. The grant is subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.

5 Property and equipment, net

| Balance, June 30, 2024      |     | $(thousands) | 674 |   |
|:----------------------------|:----|:-------------|----:|:--|
| Depreciation                |     |              | (17 | ) |
| Balance, September 30, 2024 |     |              | 657 |   |

<div align='center'>F-3 9</div>

At September 30, 2024, the total capitalized cost of property and equipment was $ 879(June 30, 2024 - $ 879),of which $ 499is not in use. The Company has recognized $ 17(2023 - $ 15) in depreciation expense in the three months ended September 30, 2024, on equipment in use.

6 Accounts payable and accrued liabilities

|                     |     | September 30,2024$(in thousands) |       |     | June 30,2024$(in thousands) |       |
| Trade payables      |     |                                  | 1,871 |     |                             | 1,464 |
| Accrued liabilities |     |                                  |   336 |     |                             |   743 |
| Balance             |     |                                  | 2,207 |     |                             | 2,207 |

7 Related party transactions Valent Technologies, LLC Agreements On November 20, 2023, Dr. Brown was terminated from his position as the Company’s Chief Scientific Officer